Oral Antidiabetic Drugs Market Growth, Size, Trends Analysis - By Disease Type, By Drug Class, By Medication Type, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Oral Antidiabetic Drugs Market Introduction and Overview

According to SPER market research, 'Global Oral Antidiabetic Drugs Market Size- By Disease Type, By Drug Class, By Medication Type, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' states that the Global Oral Antidiabetic Drugs Market is predicted to reach 70.63 billion by 2034 with a CAGR of 4.13%.

People with diabetes, particularly those with type 2, can better manage and control their blood glucose levels by taking oral antidiabetic medications. These drugs can increase the body's sensitivity to insulin, decrease the liver's production of glucose, delay the intestinal absorption of carbohydrates, or increase the amount of insulin secreted by the pancreas. They are usually suggested when dietary and physical activity modifications are insufficient to sustain optimal blood sugar regulation.

Restraints: When the patents on important medications expire, generics become available, increasing price competition and decreasing profit margins. Long approval procedures and strict regulatory requirements cause delays in the launch of new treatments. Patient acceptance and doctor prescriptions may be restricted by adverse effects and safety issues, such as cardiovascular or renal hazards. High treatment costs and a lack of adequate healthcare infrastructure limit access to cutting-edge drugs in low- and middle-income areas.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Disease Type, By Drug Class, By Medication Type, By Distribution Channel

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly & Company, Glenmark Pharmaceuticals, Johnson & Johnson (Janssen Pharmaceuticals), Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda Pharmaceuticals.

Global Oral Antidiabetic Drugs Market Segmentation:

By Disease Type: Based on the Disease Type, Global Oral Antidiabetic Drugs Market is segmented as; Type 2 diabetes, Type 1 diabetes.

By Drug Class: Based on the Drug Class, Global Oral Antidiabetic Drugs Market is segmented as; Biguanides, Dipeptidyl peptidase - 4 (DPP-4) inhibitors, Sodium-glucose transport protein-2 (SGLT-2) inhibitors, Sulfonylureas, Thiazolidinediones, Meglitinides, Alpha-glucosidase inhibitors.

By Medication Type: Based on the Medication Type, Global Oral Antidiabetic Drugs Market is segmented as; Branded, Generic.

By Distribution Channel: Based on the Distribution Channel, Global Oral Antidiabetic Drugs Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacies.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25316

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Oral Antidiabetic Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Oral Antidiabetic Drugs Market

7. Global Oral Antidiabetic Drugs Market, By Disease Type (USD Million) 2021-2034

7.1. Type 2 diabetes
7.2. Type 1 diabetes

8. Global Oral Antidiabetic Drugs Market, By Drug Class (USD Million) 2021-2034

8.1. Biguanides
8.2. Dipeptidyl peptidase - 4 (DPP-4) inhibitors
- 8.2.1. Sitagliptin
- 8.2.2. Linagliptin
- 8.2.3. Vildagliptin
- 8.2.4. Saxagliptin
- 8.2.5. Alogliptin
- 8.2.6. Other DPP-4 inhibitors
8.3. Sodium-glucose transport protein-2 (SGLT-2) inhibitors
- 8.3.1. Dapagliflozin
- 8.3.2. Empagliflozin
- 8.3.3. Canagliflozin
8.4. Sulfonylureas
- 8.4.1. Glimepiride
- 8.4.2. Glipizide
- 8.4.3. Glyburide
8.5. Thiazolidinediones
8.6. Meglitinides
- 8.6.1. Repaglinide
- 8.6.2. Nateglinide
8.7. Alpha-glucosidase inhibitors
8.8. Other drug classes

9. Global Oral Antidiabetic Drugs Market, By Medication Type (USD Million) 2021-2034

9.1. Branded
9.2. Generic

10. Global Oral Antidiabetic Drugs Market, By Distribution Channel (USD Million) 2021-2034

10.1. Hospital pharmacies
10.2. Retail pharmacies
10.3. Online pharmacies

11. Global Oral Antidiabetic Drugs Market, (USD Million) 2021-2034

11.1. Global Oral Antidiabetic Drugs Market Size and Market Share

12. Global Oral Antidiabetic Drugs Market, By Region, (USD Million) 2021-2034

12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America

13. Company Profile

13.1. Astellas Pharma
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. AstraZeneca
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Bayer
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Boehringer Ingelheim
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. Bristol Myers Squibb
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. Eli Lilly and Company
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Glenmark Pharmaceuticals
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Johnson & Johnson (Janssen Pharmaceuticals)
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Merck
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Novartis
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Novo Nordisk
- 13.11.1. Company details
- 13.11.2. Financial outlook
- 13.11.3. Product summary
- 13.11.4. Recent developments
13.12. Pfizer
- 13.12.1. Company details
- 13.12.2. Financial outlook
- 13.12.3. Product summary
- 13.12.4. Recent development
13.13. Sanofi
- 13.13.1. Company details
- 13.13.2. Financial outlook
- 13.13.3. Product summary
- 13.13.4. Recent development
13.14. Takeda Pharmaceuticals
- 13.14.1. Company details
- 13.14.2. Financial outlook
- 13.14.3. Product summary
- 13.14.4. Recent development
13.15. Others